Natera Inc. priced its public offering of 5,714,286 common shares at $35 apiece.
The San Carlos, Calif.-based company also granted underwriters a 30-day option to buy up to an additional 857,142 common shares at the same price.
Gross proceeds from the offering, based on the offering size and per-share price, are expected to reach about $200 million.
The offering is expected to close on Oct. 21.
J.P. Morgan, Morgan Stanley, Cowen and Piper Jaffray are acting as joint book-running managers for the offering, while Baird and Craig-Hallum Capital Group are co-managers.
Natera offers preconception and prenatal genetic testing services. In May, its custom test to detect tumor DNA received breakthrough device designation from the U.S. Food and Drug Administration.